{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:45:45Z","timestamp":1792010745370,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200027"],"award-info":[{"award-number":["82200027"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinthera.2026.09.009","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:02:10Z","timestamp":1791950530000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relapse After Dupilumab Discontinuation in Pediatric Moderate-to-Severe Atopic Dermatitis: A Single-Center Retrospective Study From China"],"prefix":"10.1016","author":[{"given":"Lu","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Qin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Zhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-7066","authenticated-orcid":false,"given":"Lan-Fang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.09.009_bib0001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1159\/000519923","article-title":"Effectiveness of emollients in the prevention of atopic dermatitis in infants: a meta-analysis","volume":"238","author":"Xu","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0002","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0003","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0004","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12519-025-00911-9","article-title":"Antenatal depressive and anxiety symptoms in early pregnancy and offspring allergic diseases during toddlerhood","volume":"21","author":"Wu","year":"2025","journal-title":"World J Pediatr"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-3083.2012.04578.x","article-title":"Relationship between itch and psychological status of patients with atopic dermatitis","volume":"27","author":"Chrostowska-Plak","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0006","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000053748","article-title":"New aspects of itch pathophysiology: component analysis of atopic itch using the \u2018Eppendorf Itch Questionnaire\u2019","volume":"124","author":"Darsow","year":"2001","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0007","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jaci.2014.08.008","article-title":"Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches","volume":"134","author":"Leung","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-031-54513-9_3","article-title":"Atopic dermatitis: pathophysiology","volume":"1447","author":"Boothe","year":"2024","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0009","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for treatment of atopic dermatitis: current status and future prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0010","article-title":"The efficacy and safety of IL-13 inhibitors in atopic dermatitis: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0011","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0012","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.alit.2024.04.006","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Ebisawa","year":"2024","journal-title":"Allergol Int"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0013","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0014","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0017","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0018","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0019","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0020","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2020 https:\/\/ginasthma.org\/wp-content\/uploads\/2020\/06\/GINA-2020-report_20_06_04-1-wms.pdf."},{"key":"10.1016\/j.clinthera.2026.09.009_bib0021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0022","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0023","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0024","doi-asserted-by":"crossref","unstructured":"Simpson E, Beck L, Gadkari A, et al. Defining a responder on the peak pruritus numerical rating scale (NRS) in patients with moderate-to-severe atopic dermatitis: detailed analysis from randomized trials of dupilumab. Paper presented at the 75th Annual Meeting of the American Academy of Dermatology, Condition 3-7, 2017, Orlando, Fla, Abstract 4789. Available from: https:\/\/doi.org\/10.1016\/j.jaad.2017.04.376. Accessed June 01, 2017.","DOI":"10.1016\/j.jaad.2017.04.376"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0025","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15175","article-title":"Possibility of maintaining remission with topical therapy alone after withdrawal of dupilumab in Japanese patients with atopic dermatitis and their characteristics in the real world","volume":"33","author":"Watanabe","year":"2024","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0026","doi-asserted-by":"crossref","DOI":"10.1111\/cea.70093","article-title":"Real-world efficacy and safety of dupilumab retreatment in adults with relapsed atopic dermatitis: a retrospective study from China","author":"Zhang","year":"2025","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0027","first-page":"702","article-title":"Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab","volume":"23","author":"Wu","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0028","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1089\/derm.2024.0014","article-title":"Efficacy, safety, and early relapse after cessation of upadacitinib versus dupilumab in adolescents with moderate-to-severe atopic Dermatitis\u00ae: a real-world study in China","volume":"35","author":"Zhu","year":"2024","journal-title":"Dermatitis"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0029","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of IgG4 and its roles in health and disease","volume":"23","author":"Rispens","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/ijd.16388","article-title":"Cutaneous T-cell lymphoma following dupilumab use: a systematic review","volume":"62","author":"Park","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0031","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0032","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/JAA.S318892","article-title":"Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: a randomized trial","volume":"14","author":"Corren","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0033","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaci.2023.11.017","article-title":"Resident memory T cells in nonlesional skin and healed lesions of patients with chronic inflammatory diseases: appearances can be deceptive","volume":"153","author":"Migayron","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0034","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12711","article-title":"Remittive effect of dupilumab in atopic dermatitis","volume":"31","author":"Treister","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0036","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/jamadermatol.2024.2517","article-title":"Long-term effectiveness and reasons for discontinuation of dupilumab in patients with atopic dermatitis","volume":"160","author":"Boesjes","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0037","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jaci.2010.06.020","article-title":"Prediction of the incidence, recurrence, and persistence of atopic dermatitis in adolescence: a prospective cohort study","volume":"126","author":"Peters","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0038","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-019-00453-7","article-title":"Adult-onset atopic dermatitis: characteristics and management","volume":"20","author":"Vakharia","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clinthera.2026.09.009_bib0039","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:00:26Z","timestamp":1792008026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826003486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S0149291826003486"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapse After Dupilumab Discontinuation in Pediatric Moderate-to-Severe Atopic Dermatitis: A Single-Center Retrospective Study From China","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}